Clinical trials: MAB
RSV Immunization
Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.
RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months.
- Trial name
- PIPELINE-RSV (NCT07041190)
- Testing
- Abrysvo, Nirsevimab
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- PENTA Foundation
Colorectal Cancer
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances, such as radioactive iodine, to them without harming normal cells.
- Trial name
- NCT00003360
- Testing
- iodine I 131 monoclonal antibody A33
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Colorectal Cancer
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line…
- Trial name
- daNIS-3 (NCT04952753)
- Testing
- NIS793, Bevacizumab, Modified FOLFOX6
- Where
- 55 sites in United States, Australia and 15 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Non-infectious Intermediate Posterior- or Pan-uveitis
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life.
- Trial name
- NCT05414201
- Testing
- Adalimumab
- Where
- 7 sites in China
- Volunteers
- 87 people
- Sponsor
- AbbVie
Active Noninfectious Uveitis Affecting the Posterior Segment
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection.
- Trial name
- TITAN (NCT07218770)
- Testing
- REGN7041
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Regeneron Pharmaceuticals
HER2 Positive Solid Tumors
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies
- Trial name
- NCT04460456
- Testing
- SBT6050, pembrolizumab, Cemiplimab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 58 people
- Sponsor
- Silverback Therapeutics
Carcinoma, Hepatocellular
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
The primary purpose of the study is to explore whether treatment with PF-03446962 and best supportive care is better than placebo plus best supportive care in prolonging survival of patients affected by recurrent liver cancer.
- Trial name
- NCT01911273
- Testing
- PF-03446962, Best Supportive Care
- Where
- 4 sites in United States, Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
B-cell Chronic Lymphocytic Leukemia
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
This is a phase II, prospective, multicenter, open-label study to evaluate the efficacy and safety of Alemtuzumab in patients with relapse and refractory B-cell chronic lymphocytic leukemia.
- Trial name
- CLL004 (NCT01982175)
- Testing
- Alemtuzumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhangjiang Biotechnology Limited Company
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who have relapsed after achieving a complete response in…
- Trial name
- NCT01226472
- Testing
- KW-0761
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Kyowa Kirin Co., Ltd.
HER2-positive Breast Cancer
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
A randomized, multicenter, Phase I/IIa clinical study to evaluate the tolerability, safety, efficacy, pharmacokinetics and immunogenicity after single/multiple administration of recombinant anti-HER2 humanized monoclonal antibody…
- Trial name
- NCT04170595
- Testing
- GB221,2 mg/kg, GB221,6 mg/kg, Herceptin,6 mg/kg
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Genor Biopharma Co., Ltd.
Community-acquired Pneumonia, Bacterial Pneumonia
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunct therapy with standard of care antibiotics.
- Trial name
- NCT05629741
- Testing
- CMTX-101
- Where
- 8 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Clarametyx Biosciences, Inc.
Leukemia, Lymphoma
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Biological therapies such as denileukin diftitox may be able to deliver cancer-killing substances directly to non-Hodgkin's lymphoma cells.
- Trial name
- NCT00026429
- Testing
- denileukin diftitox
- Where
- 6 sites in United States
- Sponsor
- Pharmatech Oncology
Pregnancy, Abortion Early
Assessment of Early Pregnancy MAB Completion
This is a prospective study to evaluate if successful completion of a medication abortion in patients with very early pregnancy can be detected with a urine pregnancy test at 2 weeks instead of 4 weeks.
- Trial name
- NCT06893484
- Testing
- Weekly high-sensitivity urine pregnancy tests
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Washington
Axial Spondyloarthritis
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis
The aim of the study is to evaluate the efficacy, safety, immunogenicity, pharmacokinetics and pharmacodynamics of two doses of study drug (BCD-180) in comparison with placebo in patients with active radiographic axial…
- Trial name
- ELEFTA (NCT05445076)
- Testing
- anti-TRBV9 monoclonal antibody, low dose, anti-TRBV9 monoclonal antibody, high dose
- Where
- 2 sites in Russia
- Volunteers
- 250 people
- Sponsor
- Biocad
ALK Fusion-positive Non-small Cell Lung Cancer
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
This prospective single-arm clinical study plans to enroll 29 participants with unresectable stage IIIB-IV ALK fusion-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT07674368
- Testing
- Recaticimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Hunan Cancer Hospital
Advanced Malignancies
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.
- Trial name
- NCT03763149
- Testing
- IBI188
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Cancer
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective with or without monoclonal antibody therapy in treating patients who develop RSV pneumonia…
- Trial name
- NCT00014391
- Testing
- palivizumab, ribavirin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Transfusion Dependent Thalassemia
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
Graft-versus-host disease (GVHD) is a major factor affecting the efficacy and quality of life of alternative donor transplantation in thalassemia major (TM), severely limiting the clinical application of alternative donor…
- Trial name
- NCT06657391
- Testing
- recombinant humanized anti-CD25 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 396 people
- Sponsor
- Rongrong Liu
HR+/HER2- Breast Cancer
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
Our center plans to conduct a prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with Anlotinib and Benmelstobart in the treatment of HR+/HER2- breast…
- Trial name
- NCT06874933
- Testing
- Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart
- Where
- 3 sites in China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Brain and Central Nervous System Tumors
Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody TNT-1/B (^131I MOAB TNT-1/B), can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00128635
- Testing
- iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.